215 related articles for article (PubMed ID: 25752855)
1. Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.
Patel JM; Kim MC; Vartabedian VF; Lee YN; He S; Song JM; Choi HJ; Yamanaka S; Amaram N; Lukacher A; Montemagno CD; Compans RW; Kang SM; Selvaraj P
Nanomedicine; 2015 Jul; 11(5):1097-107. PubMed ID: 25752855
[TBL] [Abstract][Full Text] [Related]
2. Comment on Patel et al; "Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses" Nanomedicine, 2015. 11(5): p. 1097-107.
Metzner C; Salmons B; Günzburg WH; Dangerfield JA
Nanomedicine; 2016 Apr; 12(3):665-666. PubMed ID: 26593637
[No Abstract] [Full Text] [Related]
3. Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses.
Liu J; Ren Z; Wang H; Zhao Y; Wilker PR; Yu Z; Sun W; Wang T; Feng N; Li Y; Wang H; Ji X; Li N; Yang S; He H; Qin C; Gao Y; Xia X
Int Immunopharmacol; 2018 Oct; 63():119-128. PubMed ID: 30081250
[TBL] [Abstract][Full Text] [Related]
4. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
Liu WC; Liu YY; Chen TH; Liu CC; Jan JT; Wu SC
Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.
Skountzou I; Quan FS; Gangadhara S; Ye L; Vzorov A; Selvaraj P; Jacob J; Compans RW; Kang SM
J Virol; 2007 Feb; 81(3):1083-94. PubMed ID: 17108046
[TBL] [Abstract][Full Text] [Related]
6. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
7. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.
Wang BZ; Xu R; Quan FS; Kang SM; Wang L; Compans RW
PLoS One; 2010 Nov; 5(11):e13972. PubMed ID: 21124769
[TBL] [Abstract][Full Text] [Related]
8. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
Quan FS; Huang C; Compans RW; Kang SM
J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection.
Dong Y; Ma T; Zhang X; Ying Q; Han M; Zhang M; Yang R; Li Y; Wang F; Liu R; Wu X
J Med Microbiol; 2019 Mar; 68(3):480-492. PubMed ID: 30657443
[TBL] [Abstract][Full Text] [Related]
11. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
12. Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral immunization of mice.
Ren Z; Zhao Y; Liu J; Ji X; Meng L; Wang T; Sun W; Zhang K; Sang X; Yu Z; Li Y; Feng N; Wang H; Yang S; Yang Z; Wang Z; Gao Y; Xia X
Vaccine; 2018 Sep; 36(40):5990-5998. PubMed ID: 30172635
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
14. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP].
Savard C; Laliberté-Gagné MÈ; Babin C; Bolduc M; Guérin A; Drouin K; Forget MA; Majeau N; Lapointe R; Leclerc D
Vaccine; 2012 Mar; 30(15):2535-42. PubMed ID: 22326774
[TBL] [Abstract][Full Text] [Related]
15. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
16. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
17. Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice.
Wang L; Wang YC; Feng H; Ahmed T; Compans RW; Wang BZ
Biomed Res Int; 2013; 2013():686549. PubMed ID: 23984396
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
19. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice.
Quan FS; Vunnava A; Compans RW; Kang SM
PLoS One; 2010 Feb; 5(2):e9161. PubMed ID: 20161790
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles.
Cheng LF; Wang F; Zhang L; Yu L; Ye W; Liu ZY; Ying QK; Wu XA; Xu ZK; Zhang FL
Front Cell Infect Microbiol; 2016; 6():185. PubMed ID: 28066721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
